Qian Chu[Author] - Search Results

Year	Number of Results
2004	3
2005	1
2007	2
2008	3
2009	2
2010	1
2012	1
2013	3
2014	6
2015	8
2016	10
2017	8
2018	14
2019	23
2020	27
2021	35
2022	28
2023	32
2024	11

1

Notch signaling pathway: architecture, disease, and therapeutics.

Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q. Zhou B, et al. Among authors: chu q. Signal Transduct Target Ther. 2022 Mar 24;7(1):95. doi: 10.1038/s41392-022-00934-y. Signal Transduct Target Ther. 2022. PMID: 35332121 Free PMC article. Review.

2

Gut microbiome and cancer immunotherapy.

Li W, Deng Y, Chu Q, Zhang P. Li W, et al. Among authors: chu q. Cancer Lett. 2019 Apr 10;447:41-47. doi: 10.1016/j.canlet.2019.01.015. Epub 2019 Jan 23. Cancer Lett. 2019. PMID: 30684593 Free article. Review.

3

EGFR-TKIs resistance via EGFR-independent signaling pathways.

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. Liu Q, et al. Among authors: chu q. Mol Cancer. 2018 Feb 19;17(1):53. doi: 10.1186/s12943-018-0793-1. Mol Cancer. 2018. PMID: 29455669 Free PMC article. Review.

4

Exploiting innate immunity for cancer immunotherapy.

Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Yi M, et al. Among authors: chu q. Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w. Mol Cancer. 2023. PMID: 38008741 Free PMC article. Review.

5

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance.

Huang C, Ren S, Chen Y, Liu A, Wu Q, Jiang T, Lv P, Song D, Hu F, Lan J, Sun L, Zheng X, Luo X, Chu Q, Jia K, Li Y, Wang J, Zou C, Hu J, Wang G. Huang C, et al. Among authors: chu q. Sci Adv. 2023 May 26;9(21):eade4186. doi: 10.1126/sciadv.ade4186. Epub 2023 May 26. Sci Adv. 2023. PMID: 37235656 Free PMC article.

6

Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.

Zhang H, Yang Y, Li X, Yuan X, Chu Q. Zhang H, et al. Among authors: chu q. Biomed Pharmacother. 2023 Mar;159:114248. doi: 10.1016/j.biopha.2023.114248. Epub 2023 Jan 14. Biomed Pharmacother. 2023. PMID: 36645960 Free article. Review.

7

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.

Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Li A, et al. Among authors: chu q. J Hematol Oncol. 2019 Apr 1;12(1):35. doi: 10.1186/s13045-019-0721-x. J Hematol Oncol. 2019. PMID: 30935414 Free PMC article. Review.

8

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.

Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K. Niu M, et al. Among authors: chu q. J Hematol Oncol. 2023 Aug 12;16(1):94. doi: 10.1186/s13045-023-01487-5. J Hematol Oncol. 2023. PMID: 37573354 Free PMC article.

9

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.

Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q. Liu F, et al. Among authors: chu q. Front Oncol. 2022 Mar 17;12:864666. doi: 10.3389/fonc.2022.864666. eCollection 2022. Front Oncol. 2022. PMID: 35372074 Free PMC article. Review.

10

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.

Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Yi M, et al. Among authors: chu q. J Hematol Oncol. 2022 Oct 8;15(1):142. doi: 10.1186/s13045-022-01363-8. J Hematol Oncol. 2022. PMID: 36209176 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

204 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Results by year